Pub Date : 2024-09-27DOI: 10.1016/j.jaad.2024.09.029
C Guillemin, N Bellon, M Jachiet, S Barbarot, E Bourrat, C Chiaverini, P Cougoul, M Ebbo, M Herber, T Hubiche, S Mallet, M Tauber, V Béziat, M Castelle, A Du Thanh, J Farhi, C Fieschi, B Fournier, C Gourguechon, T Guiddir, D Lipsker, N Raison-Peyron, N Garcelon, M Cheminant, F Suarez, O Hermine, S Blanche, D Moshous, N Mahlaoui, B Neven, C Bodemer, R Lévy, L Polivka
{"title":"Dupilumab in atopic-dermatitis-like eczema associated with inborn errors of immunity: a nationwide study.","authors":"C Guillemin, N Bellon, M Jachiet, S Barbarot, E Bourrat, C Chiaverini, P Cougoul, M Ebbo, M Herber, T Hubiche, S Mallet, M Tauber, V Béziat, M Castelle, A Du Thanh, J Farhi, C Fieschi, B Fournier, C Gourguechon, T Guiddir, D Lipsker, N Raison-Peyron, N Garcelon, M Cheminant, F Suarez, O Hermine, S Blanche, D Moshous, N Mahlaoui, B Neven, C Bodemer, R Lévy, L Polivka","doi":"10.1016/j.jaad.2024.09.029","DOIUrl":"https://doi.org/10.1016/j.jaad.2024.09.029","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":null,"pages":null},"PeriodicalIF":12.8,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-27DOI: 10.1016/j.jaad.2024.09.035
Yulin Sun, Yiming Shen, Qian Liu, Hao Zhang, Lingling Jia, Yi Chai, Hua Jiang, Minjuan Wu, Yufei Li
Background: Melanoma, a significant global health concern, has shown evolving epidemiological trends. Accurate estimation of melanoma's burden is essential for public health strategies and interventions.
Objectives: This study aims to estimate the incidence, mortality, and disability-adjusted life years (DALYs) for melanoma, stratified by region, gender, and age group, from 1990 to 2021.
Methods: Using data from the Global Burden of Disease (GBD) 2021, we analyzed melanoma incidence, mortality rates, and DALYs in 204 countries from 1990 to 2021. These metrics were age-standardized and stratified by age, sex, Socio-Demographic Index (SDI), region, and country. The estimated annual percentage change (EAPC) was calculated to track temporal trends.
Results: Our study shows a substantial global increase in melanoma incidence, with significant disparities between genders and age groups. Higher SDI regions had increased incidence rates, while global mortality declined, likely due to improved detection and treatment.
Limitations: The reliance on estimates and models may introduce bias due to variability in disease definitions, diagnostic criteria, and data collection methods.
Conclusion: This study underscores the dynamic nature of melanoma's burden and the need for targeted, age-specific, and gender-specific interventions. Continued research is essential to address the growing challenges posed by melanoma.
{"title":"Global Trends in Melanoma Burden: A Comprehensive Analysis from the Global Burden of Disease Study, 1990-2021.","authors":"Yulin Sun, Yiming Shen, Qian Liu, Hao Zhang, Lingling Jia, Yi Chai, Hua Jiang, Minjuan Wu, Yufei Li","doi":"10.1016/j.jaad.2024.09.035","DOIUrl":"https://doi.org/10.1016/j.jaad.2024.09.035","url":null,"abstract":"<p><strong>Background: </strong>Melanoma, a significant global health concern, has shown evolving epidemiological trends. Accurate estimation of melanoma's burden is essential for public health strategies and interventions.</p><p><strong>Objectives: </strong>This study aims to estimate the incidence, mortality, and disability-adjusted life years (DALYs) for melanoma, stratified by region, gender, and age group, from 1990 to 2021.</p><p><strong>Methods: </strong>Using data from the Global Burden of Disease (GBD) 2021, we analyzed melanoma incidence, mortality rates, and DALYs in 204 countries from 1990 to 2021. These metrics were age-standardized and stratified by age, sex, Socio-Demographic Index (SDI), region, and country. The estimated annual percentage change (EAPC) was calculated to track temporal trends.</p><p><strong>Results: </strong>Our study shows a substantial global increase in melanoma incidence, with significant disparities between genders and age groups. Higher SDI regions had increased incidence rates, while global mortality declined, likely due to improved detection and treatment.</p><p><strong>Limitations: </strong>The reliance on estimates and models may introduce bias due to variability in disease definitions, diagnostic criteria, and data collection methods.</p><p><strong>Conclusion: </strong>This study underscores the dynamic nature of melanoma's burden and the need for targeted, age-specific, and gender-specific interventions. Continued research is essential to address the growing challenges posed by melanoma.</p>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":null,"pages":null},"PeriodicalIF":12.8,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-27DOI: 10.1016/j.jaad.2024.09.033
Tejas P Joshi, Stephanie Y Zhang, Ikue Shimizu
{"title":"Equivalent disease-specific survival after Mohs micrographic surgery versus wide local excision for cutaneous leiomyosarcoma: a Surveillance, Epidemiology, and End Results (SEER) program-based analysis.","authors":"Tejas P Joshi, Stephanie Y Zhang, Ikue Shimizu","doi":"10.1016/j.jaad.2024.09.033","DOIUrl":"https://doi.org/10.1016/j.jaad.2024.09.033","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":null,"pages":null},"PeriodicalIF":12.8,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-27DOI: 10.1016/j.jaad.2024.08.080
Pelin Sagut, Dirk M Elston
{"title":"Images in Dermatology: Dermatophytosis.","authors":"Pelin Sagut, Dirk M Elston","doi":"10.1016/j.jaad.2024.08.080","DOIUrl":"https://doi.org/10.1016/j.jaad.2024.08.080","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":null,"pages":null},"PeriodicalIF":12.8,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-26DOI: 10.1016/j.jaad.2024.09.034
Elena Lucía Pinto-Pulido, Isabel Polo-Rodríguez, Elena García-Verdú, Paola Merlo-Gómez, Laura Martínez-Alcalde, Lucía Ruiz-Gutiérrez, Susana Medina-Montalvo
{"title":"Botulinum toxin for Raynaud´s phenomenon: a decade of real-world evidence.","authors":"Elena Lucía Pinto-Pulido, Isabel Polo-Rodríguez, Elena García-Verdú, Paola Merlo-Gómez, Laura Martínez-Alcalde, Lucía Ruiz-Gutiérrez, Susana Medina-Montalvo","doi":"10.1016/j.jaad.2024.09.034","DOIUrl":"https://doi.org/10.1016/j.jaad.2024.09.034","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":null,"pages":null},"PeriodicalIF":12.8,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-26DOI: 10.1016/j.jaad.2024.09.032
Kimberly N Williams, Sofia M Perez, Brandon Burroway, Antonella Tosti
{"title":"Topical Ruxolitinib in the Management of Frontal Fibrosing Alopecia and/or Lichen Planopilaris: A Single-center Retrospective Cohort Study.","authors":"Kimberly N Williams, Sofia M Perez, Brandon Burroway, Antonella Tosti","doi":"10.1016/j.jaad.2024.09.032","DOIUrl":"https://doi.org/10.1016/j.jaad.2024.09.032","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":null,"pages":null},"PeriodicalIF":12.8,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-26DOI: 10.1016/j.jaad.2024.08.079
Jinyan Zhang, Yan Wu, Fei Wang
{"title":"The association between alcohol consumption and the severity of male Androgenic Alopecia in Chinese participants: A Single-Center Cross-Sectional Study.","authors":"Jinyan Zhang, Yan Wu, Fei Wang","doi":"10.1016/j.jaad.2024.08.079","DOIUrl":"https://doi.org/10.1016/j.jaad.2024.08.079","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":null,"pages":null},"PeriodicalIF":12.8,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-26DOI: 10.1016/j.jaad.2024.09.030
Katerina Yale, Jennifer Roux, Jessica Shiu
{"title":"A Cross-sectional Study of Cutaneous Immune-Related Adverse Effects in Hispanic Patients after Immune Checkpoint Inhibitor Use for Cancer Therapy.","authors":"Katerina Yale, Jennifer Roux, Jessica Shiu","doi":"10.1016/j.jaad.2024.09.030","DOIUrl":"https://doi.org/10.1016/j.jaad.2024.09.030","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":null,"pages":null},"PeriodicalIF":12.8,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Vunakizumab, a novel anti-IL-17A antibody, has showed promising efficacy for moderate-to-severe plaque psoriasis in a phase 2 trial.
Objective: We conducted a double-blind, randomized phase 3 trial (NCT04839016) to further evaluate vunakizumab in this population.
Methods: 690 subjects were randomized (2:1) to receive vunakizumab 240 mg or placebo at weeks 0, 2, 4 and 8. At week 12, subjects on placebo were switched to vunakizumab 240 mg (weeks 12, 14, 16 and q4w thereafter). The co-primary endpoints were ≥90% improvement from baseline in the psoriasis area-and-severity index score (PASI 90) and a static Physicians Global Assessment score of 0/1 (sPGA 0/1) at week 12.
Results: At week 12, the vunakizumab group showed higher PASI 90 (76.8% vs 0.9%) and sPGA 0/1 (71.8% vs 0.4%) response rates, as well as higher PASI 75 (93.6% vs 4.0%), PASI 100 (36.6% vs 0.0%) and sPGA 0 (38.2% vs 0.0%) response rates (all two-sided P<0.0001 vs placebo). Efficacy was maintained through week 52 with continuous vunakizumab. Possible treatment-related serious adverse events occurred in 0.9% of vunakizumab-treated subjects.
Limitations: Chinese subjects only; no active comparator.
Conclusion: Vunakizumab demonstrated robust clinical response at week 12 and through week 52, with good tolerability in moderate-to-severe plaque psoriasis.
背景：新型抗IL-17A抗体武那单抗（VunakizumabVunakizumab是一种新型抗IL-17A抗体，在一项2期试验中对中重度斑块状银屑病显示了良好的疗效：我们进行了一项双盲、随机3期试验（NCT04839016），以进一步评估vunakizumab在这一人群中的疗效。方法：690名受试者被随机（2:1）分配，在第0、2、4和8周接受vunakizumab 240毫克或安慰剂治疗。在第12周，服用安慰剂的受试者转为服用vunakizumab 240毫克（第12、14、16周，此后每4周一次）。共同主要终点是在第12周时，银屑病面积和严重程度指数评分（PASI 90）比基线改善≥90%，静态医生总体评估评分为0/1（sPGA 0/1）：第12周时，武那单抗组的PASI 90（76.8% vs 0.9%）和sPGA 0/1（71.8% vs 0.4%）应答率较高，PASI 75（93.6% vs 4.0%）、PASI 100（36.6% vs 0.0%）和sPGA 0（38.2% vs 0.0%）应答率也较高（均为双侧）：结论：结论：在第12周和第52周，武那单抗在中重度斑块状银屑病患者中表现出稳健的临床反应和良好的耐受性。
{"title":"Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase 3 trial.","authors":"Kexiang Yan, Fuqiu Li, Xiaodong Bi, Ling Han, Zhenghua Zhang, Rixin Chen, Yuye Li, Litao Zhang, Xiaohua Wang, Linfeng Li, Jianyun Lu, Ai'e Xu, Sen Yang, Yan Lu, Jianfang Sun, Zhiming Li, Xiaohong Zhu, Meiying Jiang, Siping Zhang, Wenqin Wang, Yanlin Li, Zudong Meng, Hongyi Li, Kuanhou Mou, Xiuping Han, Shanshan Li, Aijun Chen, Xin Li, Donghua Liu, Chunlei Zhang, Chao Ji, Yu Wang, Hao Cheng, Xiaojing Cui, Xiaoyan Yao, Xiaoyan Bai, Guangchao Dong, Jinhua Xu","doi":"10.1016/j.jaad.2024.09.031","DOIUrl":"https://doi.org/10.1016/j.jaad.2024.09.031","url":null,"abstract":"<p><strong>Background: </strong>Vunakizumab, a novel anti-IL-17A antibody, has showed promising efficacy for moderate-to-severe plaque psoriasis in a phase 2 trial.</p><p><strong>Objective: </strong>We conducted a double-blind, randomized phase 3 trial (NCT04839016) to further evaluate vunakizumab in this population.</p><p><strong>Methods: </strong>690 subjects were randomized (2:1) to receive vunakizumab 240 mg or placebo at weeks 0, 2, 4 and 8. At week 12, subjects on placebo were switched to vunakizumab 240 mg (weeks 12, 14, 16 and q4w thereafter). The co-primary endpoints were ≥90% improvement from baseline in the psoriasis area-and-severity index score (PASI 90) and a static Physicians Global Assessment score of 0/1 (sPGA 0/1) at week 12.</p><p><strong>Results: </strong>At week 12, the vunakizumab group showed higher PASI 90 (76.8% vs 0.9%) and sPGA 0/1 (71.8% vs 0.4%) response rates, as well as higher PASI 75 (93.6% vs 4.0%), PASI 100 (36.6% vs 0.0%) and sPGA 0 (38.2% vs 0.0%) response rates (all two-sided P<0.0001 vs placebo). Efficacy was maintained through week 52 with continuous vunakizumab. Possible treatment-related serious adverse events occurred in 0.9% of vunakizumab-treated subjects.</p><p><strong>Limitations: </strong>Chinese subjects only; no active comparator.</p><p><strong>Conclusion: </strong>Vunakizumab demonstrated robust clinical response at week 12 and through week 52, with good tolerability in moderate-to-severe plaque psoriasis.</p>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":null,"pages":null},"PeriodicalIF":12.8,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-24DOI: 10.1016/j.jaad.2024.08.077
Yuying Zhang, Jenny Chung, Ryan Chen, Shiv Malhotra, Daniel Nguyen, Nikki A Levin
{"title":"Testing the ability of artificial intelligence chatbots and dermatologic diagnosis mobile applications to diagnose melanoma and seborrheic keratosis.","authors":"Yuying Zhang, Jenny Chung, Ryan Chen, Shiv Malhotra, Daniel Nguyen, Nikki A Levin","doi":"10.1016/j.jaad.2024.08.077","DOIUrl":"https://doi.org/10.1016/j.jaad.2024.08.077","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":null,"pages":null},"PeriodicalIF":12.8,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号